万隆控股(00030.HK)拟首季推售含大麻叶提取物个人护理产品
万隆控股(00030.HK)公布,计划通过旗下品牌「清香集」,推出个人护理系列产品,包括沐浴露、洗发水、精华液及唇膜,有关产品均含大麻叶提取物成份,已通过拥有「化妆品生产许可证」的第三方代工企业完成部分产品配方研发,目前正处於内部测试阶段,子公司并已初步确定该等产品的销售渠道,正与多个中国电商平台就营运网上零售店积极沟通,预期第一季度陆续向市场推售。
另外,全资子公司BL Organic株式会社已与一间日本制药公司订立谘询协议,已委任该日本药业公司作为顾问,为公司研发、生产及销售含有大麻叶提取物成份的护肤品及个人护理产品提供意见,谘询协议初步为期九个月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.